- Vaccine Name: 17D YF Vaccine plus Ig
- Target Pathogen: Viral haemorrhagic septicaemia virus
- Manufacturer: Sanofi Pasteur
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: Human Leukocyte Antigen
- Preparation: The first 64 participants received the YF vaccine from one lot. Immediately after the administration of the YF vaccine subcutaneously into the deltoid, immunoglobulin (Ig) or saline injections were administered intramuscularly into the upper outer quadrants of the buttocks. The placebo for Ig was sterile saline (0.9% sodium chloride injection, USP; Hospira Inc., Lake Forest, IL) administered similarly. Participants returned on post-vaccination days 1, 2, 3, 5, 7, 9, 11, 14, 30, and 91 for determination of viremia and immunological and safety assessment. (Edupuganti et al., 2013)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies. (Edupuganti et al., 2013)
|
